Trial Profile
An open, prospective trial investigating pharmacokinetics and safety (Part A) of the human normal immunoglobulin for intravenous infusion (IVIG) BT090 and tolerability and safety of escalating infusion rates (Part B) in patients with primary immunodeficiency disease (PID)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jun 2016
Price :
$35
*
At a glance
- Drugs Immunoglobulin G (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Biotest AG
- 16 May 2016 New trial record